Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment
B Shariat-Madar1, D Kolte2, A Verlangieri2, Z Shariat-Madar21College of Literature, Science, and the Arts, University of Michigan, Ann Arbor MI, USA; 2School of Pharmacy, Department of Pharmacology, University of Mississippi, University, MS, USAAbstract: Recently, we serendipitously discovered that...
Guardado en:
Autores principales: | B Shariat-Madar, D Kolte, A Verlangieri, et al |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c9f6b9dea2034e42bdf178ec962e2909 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment
por: Shariat-Madar Z, et al.
Publicado: (2010) -
GABAergic system in the endocrine pancreas: a new target for diabetes treatment
por: Wan Y, et al.
Publicado: (2015) -
Strategy to combat obesity and to promote physical activity in Arab countries
por: Abdulrahman O Musaiger, et al.
Publicado: (2011) -
TRC150094 attenuates progression of nontraditional cardiovascular risk factors associated with obesity and type 2 diabetes in obese ZSF1 rats
por: Shitalkumar P Zambad, et al.
Publicado: (2011) -
Past, present, and future: Critical analysis of use of gastric bands in obese patients
por: Brad Snyder, et al.
Publicado: (2010)